Dr Paul Kippax
Pharmaceutical Sector Director

Malvern Panalytical

Is this your profile?

About

Paul Kippax, PhD, leads the business development and marketing team at Malvern Panalytical as Pharmaceutical and Food Sector Director. He has a PhD in colloid science from the University of Nottingham (UK) and joined Malvern in 1997 – developing an in-depth understanding of how material characterisation techniques can address key industry challenges.

Contributions

SOLVING COMPLEX FORMULATION & DELIVERY CHALLENGES FOR INTRANASAL DRUGS

Paul Kippax discusses the analytical techniques used for in vitro characterisation of nasal sprays, and how their use can accelerate and de-risk both innovator and generic nasal drug development.

More contributions

PHYSICOCHEMICAL BIOEQUIVALENCE IN OPHTHALMIC MICROEMULSIONS

Here, Paul Kippax describes the methods by which bioequivalence can be established for ophthalmic microemulsions by in vitro testing, saving the need for costly clinical trials.

GENERIC NEBULISER BIOEQUIVALENCE: OPTIMISING ANALYTICAL STRATEGIES

Déborah Le Pennec, Laurent Vecellio, Paul Kippax and Stephane Rouquette look at the optimal application of laser diffraction and automated imaging within the context of the US FDA guidance for the in vitro demonstration of bioequivalence in a generic nebuliser.

INVESTIGATING THE DE-AGGLOMERATION PROFILES OF DPI FORMULATIONS

Paul Kippax from Malvern Instruments, Srinivas Ravindra Babu Behara, David Morton, Ian Larson and Peter Stewart from Monash University describe the use of laser diffraction to analyse dry powder behaviour.

SCOPING THE DESIGN SPACE FOR GENERIC NASAL SPRAYS

Deborah Huck-Jones and Paul Kippax discuss analytical methods that can be helpful for demonstrating bioequivalence in the development of generic nasal sprays.

Top